A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma

摘要: Study Type – Therapy (systematic review) Level of Evidence 1a What's known on the subject? and What does study add? At present, little is about role stereotactic ablative body radiotherapy in treatment primary renal cell carcinoma. The published evidence to date totals 126 patients worldwide. majority retrospective nature. The present adds context current literature by providing an overall summary evidence. OBJECTIVE •  To critically assess use (SABR) for carcinoma with particular focus local control toxicity outcomes. METHODS •  A systematic search PubMed was performed January 2012 independently two radiation oncologists using structured terms. •  Secondary manual searches were citations relevant publications abstracts major journals. •  Outcomes, techniques, biological doses scientific rigour studies analysed. RESULTS •  In total 10 (seven three prospective) identified. A wide range dose fractionation schedules found. •  A treated between one six fractions SABR. Median or mean follow-up ranged from 9 57.5 months. weighted reported 93.91% (range 84%–100%). •  The rate severe grade 3 higher adverse events 3.8% 0%–19%). 1–2 minor 21.4% 0%–93%). most commonly employed schedule 40 Gy delivered over five fractions. CONCLUSIONS •  Current suggests that SABR can be promising rates acceptable toxicity. •  However, there insufficient recommend a consensus view technique. •  This indicates need further prospective assessing this technique medically inoperable patients.